Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerance and Biodistribution of 99mTc-Fucoidan in Healthy Volunteers
NCT03422055Phase 1Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2018
- Primary completion
- May 2018
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of technetium Tc 99m fucoidan in atherosclerosis and thrombosis, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Adverse events and serious adverse events at 7 days. Status: unknown.
02
Drugs
technetium Tc 99m fucoidan
03
Conditions
atherosclerosisthrombosis
Beyond the preview
Go deeper on NCT03422055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422055.